Evidence mapPaperPMID 24793441Full record

GuidelineJournal of clinical lipidology

An assessment by the Statin Liver Safety Task Force: 2014 update.

Harold Bays, David E Cohen, Naga Chalasani, Stephen A Harrison, The National Lipid Association's Statin Safety Task Force

Registry-linked trialOpen access · bronzeAbstract readPractice Guideline
PubMed Publisher
In one paragraph

Guideline in Journal of clinical lipidology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03696940. Cited by 94 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed, 7 pooled it
14.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

Recommendations it makes

Among their recommendations was that regulatory agencies reconsider the statin-labeling recommendation at that time, which required post-statin liver enzyme testing.
2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03696940 phase3unknown status

Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina

Ran2018Enrolled120Registered outcomes6Posted comparisons0ConditionsCardiovascular Risk Factor, DyslipidemiasArmsAtorvastatin 10mg, L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg
Open the trial in the graph
3 · Its place in the literature

Who cites it

94 citing papers in PubMed, 7 syntheses or guidelines pooled it, 226 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Statins in Hepatitis B or C Patients Is Associated With Reduced Hepatocellular Carcinoma Risk: A Systematic Review and Meta-Analysis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022
    Pooled it
  4. Frontiers in pharmacology · 2022
    Pooled it
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Trial
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Management of dyslipidaemia in patients with comorbidities-facing the challenge.European heart journal. Cardiovascular pharmacotherapy · 2025
    Review
  18. Current and emerging strategies for the prevention of hepatocellular carcinoma.Nature reviews. Gastroenterology & hepatology · 2025
    Review
  19. Article
  20. Review

34 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Harold BaysLouisville Metabolic and Atherosclerosis Research Center, 3288 Illinois Avenue, Louisville, KY 40213, USA. Electronic address: hbaysmd@aol.com.
David E CohenBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Naga ChalasaniIndiana University School of Medicine, Indianapolis, IN, USA.
Stephen A HarrisonBrooke Army Medical Center, University of Texas Health Center San Antonio, Uniformed Services University of the Health Sciences, San Antonio, TX, USA.
The National Lipid Association's Statin Safety Task Force
Brigham and Women's Hospital · USIndiana University – Purdue University Indianapolis · USLouisville Metabolic and Atherosclerosis Research Center · USSan Antonio Military Medical Center · US

Funding

HEPATOCELLULAR TRANSPORT OF BILIARY PHOSPHOLIPIDSR01DK056626 · YESHIVA UNIVERSITY · 2000 to 2004
$1.3M
6 · The paper itself

Abstract

In the 2006 Report of the National Lipid Association's Statin Safety Task Force, a panel of experts in hepatology published their findings on specific questions related to the liver blood testing during statin therapy. Among their recommendations was that regulatory agencies reconsider the statin-labeling recommendation at that time, which required post-statin liver enzyme testing. Since then, the Food and Drug Administration altered statin labeling such that unless clinically indicated for other reasons, after a pre-statin therapy baseline evaluation, follow-up liver enzyme testing was not uniformly required after statin initiation. This 2014 report provides an update on interim issues relevant to statins and liver safety. Some of the points discussed include the value of baseline liver enzymes before initiating statin therapy, safety of statin use in patients with nonalcoholic fatty liver disease, potential drug interactions between statins and drugs used to treat hepatitis, the use of statins in liver transplant recipients, and the use of statins in patients with autoimmune liver disease. Finally, this panel provides diagnostic and algorithmic approaches when evaluating statin-treated patients who experience elevations in liver enzymes.

Indexed as

Antiviral AgentsCardiovascular DiseasesEvidence-Based MedicineHepatitis, AutoimmuneHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLiverLiver DiseasesLiver Function TestsLiver TransplantationNon-alcoholic Fatty Liver DiseaseVirus DiseasesAntiviral AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsCholesterolLipidLiverNational Lipid AssociationStatin

Identifiers

PMID24793441
OpenAlexW1967006339

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.